Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$0.95
<$0.01(0.16%)
At close: 4:00 PM EDT
$0.95
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$0.55 - $1.69
Previous Close$0.61
Volume18.33K
Average Volume (3M)383.80K
Market Cap
$10.00M
Enterprise Value$2.40
Total Cash (Recent Filing)$41.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding12,591,136
10 Day Avg. Volume1,056,512
30 Day Avg. Volume383,804
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.73Price Target Upside292.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$1.07M
Bulls Say, Bears Say
Bulls Say
Expanded Intellectual Property ProtectionBroad issued and pending patent coverage can protect Aprea’s precision-oncology assets from competition and support future licensing or commercialization. Potential exclusivity into 2045–2047 strengthens the long-term strategic value of successful clinical candidates.
APR-1051 Clinical Development Is AdvancingFaster enrollment and early signs of activity provide important validation for APR-1051 and could accelerate development in biomarker-defined solid tumors. Planned combination studies may broaden the addressable population if efficacy and tolerability persist.
Debt-free Balance Sheet And Extended RunwayA debt-free structure avoids interest burden and reduces near-term solvency risk. The higher cash balance and stated runway give Aprea time to conduct clinical work and generate development milestones before requiring another financing.
Bears Say
No Recurring Product RevenueAprea has no established commercial product or recurring revenue stream, so its long-term prospects depend on clinical success and eventual approval or licensing. Until then, operating results remain disconnected from customer demand and product economics.
Persistent Losses And Cash ConsumptionOngoing losses translate into real cash outflows, requiring continued external funding to sustain research and trials. This weak cash-generation profile can lead to dilution and limits financial flexibility even with the current cash runway.
Early-stage And Concentrated Pipeline RiskThe pipeline remains clinically unproven, and resource concentration on one lead program increases execution risk. Delays, safety findings, or weak efficacy for APR-1051 could materially impair the company because ATRN-119 is no longer advancing as monotherapy.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $1.69 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $10.00M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.178 by $0.108.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.07.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,591,136 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.178. Following the earnings report the stock price went up 3.485%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$3.73
▲(292.98% Upside)
Technical Analysis
Ownership Overview
6.39% Insiders
0.84% Mutual Funds
16.16% Other Institutional Investors
76.41% Public Companies and
Individual Investors